Tango Therapeutics to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025
Tango Therapeutics (NASDAQ: TNGX) announced it will release its second quarter 2025 financial results on Tuesday, August 5, 2025, before U.S. markets open. The company stated it will not host a conference call to discuss the results.
Tango Therapeutics (NASDAQ: TNGX) ha annunciato che pubblicherà i risultati finanziari del secondo trimestre 2025 martedì 5 agosto 2025, prima dell'apertura dei mercati statunitensi. L'azienda ha specificato che non terrà una conference call per discutere i risultati.
Tango Therapeutics (NASDAQ: TNGX) anunció que publicará sus resultados financieros del segundo trimestre de 2025 el martes 5 de agosto de 2025, antes de la apertura de los mercados en EE.UU. La compañía indicó que no realizará una llamada conferencia para discutir los resultados.
Tango Therapeutics (NASDAQ: TNGX)는 2025년 8월 5일 화요일 미국 시장 개장 전에 2025년 2분기 재무 실적을 발표할 예정이라고 밝혔다. 회사는 실적에 대해 논의하는 컨퍼런스 콜을 진행하지 않을 것이라고 밝혔다.
Tango Therapeutics (NASDAQ: TNGX) a annoncé qu'il publiera ses résultats financiers du deuxième trimestre 2025 le mardi 5 août 2025, avant l'ouverture des marchés américains. La société a précisé qu'elle n'organisera pas de conférence téléphonique pour discuter des résultats.
Tango Therapeutics (NASDAQ: TNGX) gab bekannt, dass das Unternehmen seine Finanzergebnisse für das zweite Quartal 2025 am Dienstag, den 5. August 2025, vor Öffnung der US-Märkte veröffentlichen wird. Das Unternehmen teilte mit, dass keine Telefonkonferenz zur Besprechung der Ergebnisse stattfinden wird.
- None.
- None.
BOSTON, July 22, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that it will report second quarter 2025 financial results on August 5, 2025, before the open of the U.S. financial markets. The company does not intend to hold a conference call.
About Tango Therapeutics
Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit www.tangotx.com.
Investors and Media:
Elizabeth Hickin
IR@tangotx.com
media@tangotx.com
Source: Tango Therapeutics, Inc.
FAQ
When will Tango Therapeutics (NASDAQ: TNGX) report Q2 2025 earnings?
Will Tango Therapeutics hold an earnings call for Q2 2025 results?
What time will TNGX release its second quarter 2025 earnings?
Where can investors access Tango Therapeutics Q2 2025 financial results?
